Genta Incorporated announced preliminary results that show a high objective response rate in a pilot study of patients with advanced melanoma that incorporates the Company’s lead oncology product, Genasense® (oblimersen sodium) Injection, administered for the first time as a 1-hour high-dose intravenous (IV) infusion. [More]

Ligand Pharmaceuticals Incorporated today announced that data from a preclinical study on its selective androgen receptor modulator (SARM) LGD-4033 was featured in a poster presentation at the 62nd Annual Meeting of the Gerontology Society of America in Atlanta. LGD-4033 exhibited desirable in vivo efficacy on skeletal muscle and bone measurements in animal models of male hypogonadism and postmenopausal osteoporosis. [More]

Medartis, Inc. will serve as the sole sponsor of the first USA International Bone Research Association (IBRA) Symposium and Workshop. The focus of the workshop and symposium is the upper extremity, trauma and reconstruction of the wrist and hand. The event will be held in Miami, Florida at the DaVinci Center and begins today, Friday, November 20 and will conclude on Saturday, November 21. [More]

Smith & Nephew Orthopaedics Division is pleased to announce the signing of a technology development contract with the United States Department of Defense that may lead to the creation of a fracture fixation system intended to revolutionize the treatment of the limbs of soldiers who sustain battlefield injuries. [More]

A landmark, 25-year review of cases in which surgeons had to remove the lower portion of the body from the waist down for severe pelvic bone infections shows the therapy can add years and quality of life to survivors, say researchers at UT Southwestern Medical Center. [More]

Research and Markets (http://www.researchandmarkets.com/research/4b82d8/cancer_therapies) has announced the addition of the "Cancer Therapies - Global Market Opportunities" report to their offering. [More]

A synthetic bone matrix offers hope for babies born with craniosynostosis, a condition that causes the plates in the skull to fuse too soon. Implants replacing some of the infant's bone with the biodegradable matrix could eliminate some of the operations currently used to treat the condition. [More]

VisEn Medical Inc., a leader in fluorescence in vivo imaging from research through medicine, announced today the commercial launch of its new OsteoSense® 800 imaging agent for targeting areas of bone turnover and microcalcification in vivo. The new 800 nm OsteoSense agent complements VisEn's OsteoSense 680 and 750 products, and is expected to further expand the utilization of this agent family in enabling in vivo detection, measurement and monitoring of skeletal changes in a wide range of disease states, including arthritis, osteoporosis, and cancer metastasis. [More]

Continuing to drive innovation in endovascular aortic repair (EVAR), Medtronic, Inc., today announced the introduction of an imaging and visualization service for endovascular specialists who use the company’s market-leading portfolio of stent grafts to treat aortic aneurysms. Aortic aneurysms affect more than one million people in the United States alone and can rupture with fatal consequences if left untreated. [More]

PanGenex Corporation announced that due to promising pre-clinical results from its clinical trial at the Cardiovascular Institute of the South (http://www.cardio.com/site1.php), the Company will extend its trial to two additional sites. [More]

An analysis of patients with a syndrome similar to the genetic disorder, neurofibromatosis type 1, indicates that diagnosis may be difficult because of shared clinical findings, such as certain pigmentary characteristics, according to a study in the November 18 issue of JAMA. [More]

Genentech, Inc., a wholly-owned member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), and Biogen Idec announced today that the U.S. Food and Drug Administration (FDA) issued a complete response on the companies’ applications for Rituxan® (rituximab) plus fludarabine and cyclophosphamide (FC) for the treatment of people with previously untreated and previously treated chronic lymphocytic leukemia (CLL). [More]

Smoking cigarettes not only contributes to lung cancer and emphysema, it also leads to back pain and spine problems, according to recent studies and observations from leading neurosurgeons in Chicago. [More]

Jackson Laboratory Professor Gary Churchill wants to change that. With a new two-year, $1 million grant from the National Cancer Institute, Churchill is launching a radical new approach to testing three chemotherapeutic drugs for potential toxic effects. [More]

Spineology Inc., developer and manufacturer of minimally invasive spinal surgery devices, announced today that it has received FDA clearance for its minimally invasive surgery (MIS) Capture™ Facet Screw System. [More]